Immunoglobulin variants
AssigneeNovartis AG
InventorsJohn Blankenship, Justine Celine Patricia Guyot, Brian Holmberg, Sebastien Irigaray, Darko Skegro
Life of this patent
Estimating the term…
Abstract
The present invention provides an Fc variant of a parent IgA Fc polypeptide, wherein the Fc variant exhibits altered binding to FcαRs, wherein the Fc variant comprises at least one amino acid modification in the Fc region of the parent Fc polypeptide.
Claims11
An Fc variant of a parent Fc polypeptide comprised within a human IgA2 antibody, wherein the Fc variant exhibits altered binding to a FcαR or altered antibody dependent cell-mediated cytotoxicity (ADCC) as compared to the parent Fc polypeptide, wherein the Fc variant comprises at least one amino acid modification in the Fc region of the parent Fc polypeptide, wherein the at least one amino acid modification is selected from the group consisting of:
- Q_CH2.94_E,
- N_CH2.97_Y,
- S_CH3.45_D,
- M_CH3.105_Y,
- Q_CH3.118_Y,
- Q_CH2.94_E/N_CH2.97_Y,
- Q_CH2.94_E/S_CH3.45_D,
- Q_CH2.94_E/M_CH3.105_Y,
- N_CH2.97_Y/S_CH3.45_D,
- N_CH2.97_Y/M_CH3.105_Y,
- S_CH3.45_D/M_CH3.105_Y,
- M_CH3.105_Y/Q_CH3.118_Y,
- Q_CH2.94_E/N_CH2.97_Y/M_CH3.105_Y,
- N_CH2.97_Y/S_CH3.45_D/M_CH3.105_Y,
- Q_CH2.94_E/S_CH3.45_D/M_CH3.105_Y,
- M_CH3.105 Y/Q_CH3.118_Y/S_CH3.45_D,
- Q_CH2.94_E/N_CH2.97_Y/S_CH3.45_D,
- Q_CH2.94_E/N_CH2.97_Y/S_CH3.45_D/M_CH3.105_Y,
- Q_CH2.94_E/N_CH2.97_Y/M_CH3.105_Y/Q_CH3.118_Y,
- Q_CH2.94_E/N_CH2.97_Y/S_CH3.45_D/M_CH3.105_Y/Q_CH3.118_Y,
- A_CH2.10_S,
- L_CH2.89_I,
- G_CH2.91_V,
- N_CH2.97_H,
- G_CH2.99_W,
- E_CH3.109_D,
- L_CH3.124_F, and
- L_CH2.89_I/G_CH2.91_V/Q_CH2.94_E/N_CH2.97_Y/G_CH2.99_W,
- wherein numbering of the amino acid modification is according to IMGT numbering for C-domain.
Dependencies are inferred from the claim text.